Correction to: KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014)

Bo Yu; Fei Luo; Bowen Sun; Wenxue Liu; Qiqi Shi; Shi Yuan Cheng; Ceshi Chen; Guoqiang Chen; Yanxin Li; Haizhong Feng

doi:10.1002/advs.202105793

Correction to: KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014)

Bo Yu, Fei Luo, Bowen Sun, Wenxue Liu, Qiqi Shi, Shi Yuan Cheng, Ceshi Chen, Guoqiang Chen, Yanxin Li, Haizhong Feng

Neurology

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Abstract

Adv. Sci. 2021, 8, 2100014 DOI: 10.1002/advs.202100014 In the originally published article, the representative BLI images of treated mice in Figure 6D present the wrong samples (the third in the second row, and the third in the fourth row). The correct Figure 6D is shown below. The authors declare that this correction does not affect the description, interpretation, or the original conclusions of the manuscript. The authors regret the inconvenience this error may have caused. 6 Figure (Figure presented.) Targeting KAT6A sensitizes PD-L1 immunotherapy in TNBC by decreasing MDSCs recruitment. D) Representative BLI images of treated mice on Day 21.

Original language	English (US)
Article number	2105793
Journal	Advanced Science
Volume	9
Issue number	3
DOIs	https://doi.org/10.1002/advs.202105793
State	Published - Jan 25 2022

ASJC Scopus subject areas

Engineering(all)
Physics and Astronomy(all)
Chemical Engineering(all)
Materials Science(all)
Biochemistry, Genetics and Molecular Biology (miscellaneous)
Medicine (miscellaneous)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/advs.202105793

Fingerprint

Dive into the research topics of 'Correction to: KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014)'. Together they form a unique fingerprint.

Cite this

Yu, B., Luo, F., Sun, B., Liu, W., Shi, Q., Cheng, S. Y., Chen, C., Chen, G., Li, Y., & Feng, H. (2022). Correction to: KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014). Advanced Science, 9(3), Article 2105793. https://doi.org/10.1002/advs.202105793

@article{ed21c08d7ef6411eab8e0a5560be6f89,

title = "Correction to: KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014)",

abstract = "Adv. Sci. 2021, 8, 2100014 DOI: 10.1002/advs.202100014 In the originally published article, the representative BLI images of treated mice in Figure 6D present the wrong samples (the third in the second row, and the third in the fourth row). The correct Figure 6D is shown below. The authors declare that this correction does not affect the description, interpretation, or the original conclusions of the manuscript. The authors regret the inconvenience this error may have caused. 6 Figure (Figure presented.) Targeting KAT6A sensitizes PD-L1 immunotherapy in TNBC by decreasing MDSCs recruitment. D) Representative BLI images of treated mice on Day 21.",

author = "Bo Yu and Fei Luo and Bowen Sun and Wenxue Liu and Qiqi Shi and Cheng, {Shi Yuan} and Ceshi Chen and Guoqiang Chen and Yanxin Li and Haizhong Feng",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Advanced Science published by Wiley-VCH GmbH",

year = "2022",

month = jan,

day = "25",

doi = "10.1002/advs.202105793",

language = "English (US)",

volume = "9",

journal = "Advanced Science",

issn = "2198-3844",

publisher = "Wiley-VCH Verlag",

number = "3",

}

Yu, B, Luo, F, Sun, B, Liu, W, Shi, Q, Cheng, SY, Chen, C, Chen, G, Li, Y & Feng, H 2022, 'Correction to: KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014)', Advanced Science, vol. 9, no. 3, 2105793. https://doi.org/10.1002/advs.202105793

Correction to: KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014). / Yu, Bo; Luo, Fei; Sun, Bowen et al.
In: Advanced Science, Vol. 9, No. 3, 2105793, 25.01.2022.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction to

T2 - KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014)

AU - Yu, Bo

AU - Luo, Fei

AU - Sun, Bowen

AU - Liu, Wenxue

AU - Shi, Qiqi

AU - Cheng, Shi Yuan

AU - Chen, Ceshi

AU - Chen, Guoqiang

AU - Li, Yanxin

AU - Feng, Haizhong

PY - 2022/1/25

Y1 - 2022/1/25

N2 - Adv. Sci. 2021, 8, 2100014 DOI: 10.1002/advs.202100014 In the originally published article, the representative BLI images of treated mice in Figure 6D present the wrong samples (the third in the second row, and the third in the fourth row). The correct Figure 6D is shown below. The authors declare that this correction does not affect the description, interpretation, or the original conclusions of the manuscript. The authors regret the inconvenience this error may have caused. 6 Figure (Figure presented.) Targeting KAT6A sensitizes PD-L1 immunotherapy in TNBC by decreasing MDSCs recruitment. D) Representative BLI images of treated mice on Day 21.

AB - Adv. Sci. 2021, 8, 2100014 DOI: 10.1002/advs.202100014 In the originally published article, the representative BLI images of treated mice in Figure 6D present the wrong samples (the third in the second row, and the third in the fourth row). The correct Figure 6D is shown below. The authors declare that this correction does not affect the description, interpretation, or the original conclusions of the manuscript. The authors regret the inconvenience this error may have caused. 6 Figure (Figure presented.) Targeting KAT6A sensitizes PD-L1 immunotherapy in TNBC by decreasing MDSCs recruitment. D) Representative BLI images of treated mice on Day 21.

UR - http://www.scopus.com/inward/record.url?scp=85123464290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123464290&partnerID=8YFLogxK

U2 - 10.1002/advs.202105793

DO - 10.1002/advs.202105793

M3 - Comment/debate

C2 - 35075800

AN - SCOPUS:85123464290

SN - 2198-3844

VL - 9

JO - Advanced Science

JF - Advanced Science

IS - 3

M1 - 2105793

ER -

Correction to: KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer (Advanced Science, (2021), 8, 20, (2100014), 10.1002/advs.202100014)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this